B Group Inc. Buys New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

B Group Inc. bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 260,000 shares of the company's stock, valued at approximately $7,233,000. Akero Therapeutics accounts for about 4.4% of B Group Inc.'s investment portfolio, making the stock its 6th largest position. B Group Inc. owned about 0.37% of Akero Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Akero Therapeutics by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company's stock valued at $103,057,000 after buying an additional 27,830 shares during the period. SG Americas Securities LLC raised its position in Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after acquiring an additional 583,486 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock valued at $15,042,000 after acquiring an additional 8,096 shares during the period. JPMorgan Chase & Co. boosted its position in Akero Therapeutics by 8.2% in the 4th quarter. JPMorgan Chase & Co. now owns 528,207 shares of the company's stock worth $14,695,000 after purchasing an additional 40,161 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Akero Therapeutics by 6,229.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 449,110 shares of the company's stock worth $12,495,000 after purchasing an additional 442,014 shares during the period.

Akero Therapeutics Price Performance

AKRO stock traded up $1.38 during trading on Thursday, hitting $40.99. The stock had a trading volume of 1,873,243 shares, compared to its average volume of 865,124. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The company's 50-day moving average price is $42.60 and its two-hundred day moving average price is $36.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a market capitalization of $3.26 billion, a P/E ratio of -10.93 and a beta of -0.18.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Ratings Changes

AKRO has been the topic of a number of recent analyst reports. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. HC Wainwright increased their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. UBS Group upped their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics has an average rating of "Buy" and a consensus target price of $76.29.

Insider Buying and Selling

In other Akero Therapeutics news, insider Catriona Yale sold 9,073 shares of the firm's stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $37.91, for a total value of $343,957.43. Following the transaction, the insider now directly owns 95,034 shares of the company's stock, valued at $3,602,738.94. This trade represents a 8.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Patrick Lamy sold 5,000 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total value of $285,150.00. Following the transaction, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. This represents a 12.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 341,309 shares of company stock worth $15,863,578 and have sold 287,458 shares worth $13,689,886. 7.94% of the stock is currently owned by company insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.